Yahoo Finance Brokers Are Upgrading Their Views On Armata Pharmaceuticals Inc. (NYSEMKT:ARMP) With These New Forecasts
Armata Pharmaceuticals Inc. (NYSEMKT:ARMP) shareholders will have a reason to smile today, with the analysts making substantial upgrades to next year's forecasts. Consensus estimates suggest investors could expect greatly increased statutory revenues and earnings per share, with the analysts modelling a real improvement in business performance.
After this upgrade, Armata Pharmaceuticals' four analysts are now forecasting revenues of US$3.3m in 2021. This would be a sizeable improvement in sales compared to the last 12 months. Losses are predicted to fall substantially, shrinking 45% to US$0.78. Yet before this consensus update, the analysts had been forecasting revenues of US$1.8m and losses of US$0.89 per share in 2021. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a sizeable increase to their revenue forecasts while also reducing the estimated loss as the business grows towards breakeven.
View our latest analysis for Armata Pharmaceuticals
The Bottom Line
The highlight for us was that the consensus reduced its estimated losses next year, perhaps suggesting Armata Pharmaceuticals is moving incrementally towards profitability. With a serious upgrade to expectations, it might be time to take another look at Armata Pharmaceuticals.
Analysts are definitely bullish on Armata Pharmaceuticals, but no company is perfect. Indeed, you should know that there are several potential concerns to be aware of, including major dilution from new stock issuance in the past year. For more information, you can click through to our platform to learn more about this and the 3 other flags we've identified .
Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies that insiders are buying.
This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.
